Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Amylyx’s Relyvrio Could See Fast Sales Growth, But Also Spark Pricing Debate
Interpret Survival Analysis “Cautiously,” Label Advises
Sep 30 2022
•
By
Alaric DeArment
The FDA approved Amylyx's Relyvrio for amyotrophic lateral sclerosis • Source: Shutterstock
More from New Products
More from Scrip